Neoadjuvant targeted therapy for resectable EGFR-mutant non-small cell lung cancer: Current status and future...

Area of Science:

• Oncology
• Pharmacology

Background:

• Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are standard for metastatic non-small cell lung cancer (NSCLC) with EGFR mutations.
• EGFR-TKIs offer improved prognosis and reduced toxicity compared to chemotherapy.
• The preoperative use of EGFR-TKIs in resectable NSCLC is an emerging area of research.

Purpose of the Study:

• To review current evidence on neoadjuvant EGFR-TKIs for resectable EGFR-mutated NSCLC.
• To discuss potential clinical strategies for preoperative EGFR-TKI-based multimodality therapy.

Main Methods:

• Mini-review of existing literature on neoadjuvant EGFR-TKIs in resectable NSCLC.
• Analysis of potential treatment strategies.

Main Results:

• The field of neoadjuvant targeted therapy for EGFR-mutated resectable NSCLC is still developing.
• Evidence suggests potential benefits of preoperative EGFR-TKI administration.

Conclusions:

• Neoadjuvant EGFR-TKIs represent a promising therapeutic avenue for resectable EGFR-mutated NSCLC.
• Further research is needed to establish optimal preoperative EGFR-TKI-based multimodality treatment strategies.